Maravai Lifesciences is expected to report Q3 2026 revenue of $43.56 million and an adjusted EPS of -$0.07, with the current $7.57 share price trading approximately 14% below the $8.67 consensus target.
Investors are primarily focused on the revenue performance of the TriLink BioTechnologies segment and the commercial pull-through of CleanCap® technology in non-COVID mRNA programs.
Following a significant workforce restructuring in late 2025, the market is scrutinizing the company's ability to maintain positive Adjusted EBITDA and expand margins.
The adoption rate of the "ModTail" product line and the operational ramp of the new GMP enzyme manufacturing facility will be key indicators of Maravai's growth trajectory in the cell and gene therapy markets.